BamSEC and AlphaSense Join Forces
Learn More

Halozyme Therapeutics Inc.

NASDAQ: HALO    
Share price (12/20/24): $46.96    
Market cap (12/20/24): $5.975 billion
Search in Documents
Key Exhibits
External Links

Indentures Filter

EX-4.1
from 8-K 101 pages Halozyme Therapeutics, Inc. and the Bank of New York Mellon Trust Company, N.A. as Trustee Indenture Dated as of August 18, 2022 1.00% Convertible Senior Notes Due 2028
12/34/56
EX-4.5
from 10-K 3 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.2
from 8-K 12 pages Form of Note [Insert Global Note Legend, if Applicable] [Insert Restricted Note Legend, if Applicable] [Insert Non-Affiliate Legend] Halozyme Therapeutics, Inc. 0.25% Convertible Senior Note Due 2027
12/34/56
EX-4.1
from 8-K 102 pages Halozyme Therapeutics, Inc. and the Bank of New York Mellon Trust Company, N.A. as Trustee Indenture Dated as of March 1, 2021 0.25% Convertible Senior Notes Due 2027
12/34/56
EX-4.3
from 10-K 3 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.2
from 8-K 13 pages This Is a Global Note Within the Meaning of the Indenture Hereinafter Referred to and Is Registered in the Name of the Depositary or a Nominee of the Depositary, Which May Be Treated by the Company, the Trustee and Any Agent Thereof as the Owner and Holder of This Note for All Purposes
12/34/56
EX-4.1
from 8-K 99 pages Halozyme Therapeutics, Inc. and the Bank of New York Mellon Trust Company, N.A. as Trustee Indenture Dated as of November 18, 2019 1.25% Convertible Senior Notes Due 2024
12/34/56
EX-4.7
from S-3ASR 28 pages Halozyme Therapeutics, Inc., Issuer and [Trustee], Trustee Indenture Dated as of , 20 Subordinated Debt Securities
12/34/56
EX-4.6
from S-3ASR 28 pages Halozyme Therapeutics, Inc., Issuer and [Trustee], Trustee Indenture Dated as of , 20 Senior Debt Securities
12/34/56
EX-4.6
from S-3ASR 32 pages Halozyme Therapeutics, Inc., [Trustee], Trustee Indenture Dated as of , 20 Subordinated Debt Securities Indenture Article 1 Definitions
12/34/56
EX-4.5
from S-3ASR 35 pages Halozyme Therapeutics, Inc., [Trustee], Trustee Indenture Dated as of , 20 Senior Debt Securities 1
12/34/56
EX-4.2
from S-3 33 pages Halozyme Therapeutics, Inc., Issuer and [Trustee], Trustee Indenture Dated as of ___, 20__ Subordinated Debt Securities
12/34/56
EX-4.1
from S-3 32 pages Halozyme Therapeutics, Inc., Issuer and [Trustee], Trustee Indenture Dated as of ___, 20___ Senior Debt Securities
12/34/56
EX-4.2
from S-3 51 pages Halozyme Therapeutics, Inc., Issuer and [Trustee], Trustee Indenture Dated as of ___, 2008 Subordinated Debt Securities
12/34/56
EX-4.1
from S-3 49 pages Halozyme Therapeutics, Inc., Issuer and [Trustee], Trustee Indenture Dated as of ___, 2008 Senior Debt Securities
12/34/56
EX-4.1
from SC 13D/A 6 pages Halozyme Therapeutics, Inc. Callable Stock Purchase Warrant 136,300 Shares
12/34/56
EX-4.1
from 10-K 41 pages Halozyme Therapeutics, Inc. and Corporate Stock Transfer as Rights Agent Rights Agreement Dated as of May 4, 2006, as Amended
12/34/56
EX-4.1
from 8-K 54 pages Halozyme Therapeutics, Inc. and Corporate Stock Transfer as Rights Agent Rights Agreement Dated as of May 4, 2006 Rights Agreement
12/34/56
EX-4.2
from S-3 ~50 pages Indenture or similar
12/34/56
EX-4.1
from S-3 ~50 pages Indenture or similar
12/34/56